Clinical Trials Browser

Phase 2/3 × Squamous NSCLC × pembrolizumab × Clear all

NCT07318883 2026-01-06

A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer

Phase 2/3 Not yet recruiting

Squamous NSCLC